Automated And Closed Cell Therapy Processing Systems Market Size, Share & Trends Analysis Report By Workflow (Separation, Expansion), By Type (Non-stem Cell, Stem Cell), By Scale, And Segment Forecasts, 2021 - 2028

Report Overview

The global automated and closed cell therapy processing systems market size was valued at USD 615.0 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 21.7% from 2021 to 2028. The growing popularity of regenerative medicines & cell therapies coupled with a range of benefits offered by automation technologies for the development of these therapies is expected to propel the market growth. In addition, the growing integration of software technologies and advanced therapy development processes is also projected to boost the market. Furthermore, rising investments by bio manufacturers for the development of cellular therapy products through rounds of series funding are anticipated to offer lucrative opportunities to or the market.

In recent years, there has been massive growth in clinical trials associated with advanced therapies. This growth has led to an increase in demand for advanced and automated technologies to achieve high throughput and yield. This can be attributed to the fact that automated and closed systems offer better cell handling capabilities and reduce the possibility of errors during bioprocessing.

The availability of a range of systems to offer both automated integrated workflow solutions and partial automation is expected to spur the adoption rate in the space. Furthermore, the system also enables continuous monitoring of controlled therapy processing, which is being conducted for the development of new therapeutic platforms. In addition, integrated intelligent algorithms facilitate high precision. Market players are actively engaged in the development of infrastructure to leverage the production of automated systems.

For instance, in June 2021, the collaboration of Lonza and Cell Point announced its plan to utilize the Cocoon platform for the development of T-cell-based therapies. The project is being conducted to provide a proof of concept for Point-of-Care (POC) production to optimize the supply chain operations. Also, as automated systems can enhance analytical testing and facilitate quality control, the systems are expected to witness substantial acceptance during the forecast period.

Workflow Insights

The expansion segment accounted for the largest revenue share of more than 35% in 2020. The growth is majorly attributed to the presence of a substantial number of products offered under this segment. Moreover, increasing partnerships among market players for the adoption and application of systems offered under this segment is driving the growth.

For instance, Angiocrine Bioscience has implemented Terumo BCT’s quantum cell expansion system to accelerate its cell therapy research. On the other hand, separation workflow is estimated to register the fastest CAGR during the forecast period. The cell separation process is carried out across various cellular experiments, such as molecular analysis, cellular genetic modification, production of hybridomas, and other cell research & analysis-related applications.

A growing number of research activities for these applications in academic universities and other research settings is anticipated to accelerate the segment growth. Apart from expansion and separation, the workflow segment comprises apheresis, fill-finish, cryopreservation, and others. Cryopreservation and apheresis workflows are also projected to register considerable growth owing to the increasing awareness and acceptance of regenerative medicines.

Type Insights

The non-stem cell therapy segment captured the maximum revenue share of over 61% in 2020 and is anticipated to register the fastest CAGR during the forecast period. An increasing number of product launches for non-stem cell therapy applications is expected to drive the segment growth. Furthermore, the success of CAR-T therapies has directed investment towards non-stem cell therapy development, thereby driving the segment revenue.

Companies are extensively engaging in partnerships and collaboration with an aim to develop new regenerative medicines for the treatment of chronic conditions. Such research projects majorly focus on applications of non-stem cells, consequently driving the non-stem cell therapy segment growth. Moreover, growing emphasis on cell and tissue-based engineering due to massive clinical potential is also expected to accelerate the segment growth during the forecast period.

The stem cell therapy segment is anticipated to witness a significant growth rate during the forecast period. Increasing awareness about therapeutic benefits offered by stem cell therapies and rising research activities associated with drug efficacy and disease understanding is expected to have a constructive impact on the growth of the stem cell therapy segment.

Scale Insights

The pre-commercial/R&D scale segment dominated the global market in 2020 with a revenue share of more than 72%.At present, the market is relatively niche due to a limited number of products. Moreover, the majority of the companies are introducing their products only for research purposes. For instance, Cellares Inc. is planning to introduce its automated cell therapy machine in 2023.This fact is prominently driving the pre-commercial/R&D scale segment growth.

In addition, the adoption of automated systems by research institutes due to the growing number of clinical trials for cell therapies is also projected to accelerate segment growth. The laboratories and research institutes are witnessing a range of benefits due to the adoption of automated systems. According to a recent study published on NCBI, automated systems assist in achieving high-speed processing and reliability of data.

The commercial-scale segment is expected to register the fastest CAGR from 2021 to 2028. The increasing prevalence of chronic conditions, such as cancer, is encouraging companies to develop enhanced cell-therapy-based therapeutic platforms. Moreover, the market players are also focusing on cost optimization, thereby contributing to the segment growth.

Regional Insights

North America accounted for the largest revenue share of over 45.5%in 2020. This high share was majorly attributed to the increased technological adoption for cell therapy processing and emphasis on high precision & production throughput. The regional market will expand further at a steady CAGR from 2021 to 2028 as the healthcare domain in the region is witnessing a significant demand for regenerative medicines.

Growing investments by market players as well as research institutes are also expected to play a vital role in the region’s growth. Europe and Asia are anticipated to exhibit significant growth rates during the forecast period. A strong facility network and workforce in European countries are anticipated to fuel the market growth in the region.

Over the recent year, a series of fully automated platforms were introduced across European countries, which is capable of supporting the bioprocess workflows from start to end. On the other hand, the increasing government and private investments, rising healthcare needs, and establishment of accelerated approval pathways are the key driving factors for the notable growth of the market in Asia Pacific.

Key Companies & Market Share Insights

Key companies are implementing extensive strategic initiatives in the field of cell therapy automation to address the unmet needs of consumers. Technological partnerships & collaborations, mergers & acquisitions, product introductions & approvals, regional expansions, and strategic initiatives are some key strategies adopted by the market participants to gain higher market shares.

For instance, in February 2021, Cytiva and Brooks Life sciences agreed to extend the capabilities of the automated cold chain. The companies are working together to enhance the cryogenic cold chain capabilities of Cytiva’s automated cold chain system. Some of the prominent players in the global automated and closed cell therapy processing systems market include:

• MiltenyiBiotec

• Lonza

• Fresenius Kabi

• Cytiva (Danaher Corp.)

• BioSpherix, Ltd.

• Terumo Corporation

• Sartorius AG

• ThermoGenesis Holdings, Inc.

• Cellares Inc.

• Thermo Fisher Scientific, Inc.

Automated And Closed Cell Therapy Processing Systems Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this report, Grand View Research has segmented the global automated and closed cell therapy processing systems market report on the basis of workflow, type, scale, and region:

• Workflow Outlook (Revenue, USD Million, 2017 - 2028)

  • Separation

  • Expansion

  • Apheresis

  • Fill- Finish

  • Cryopreservation

  • Others

• Type Outlook (Revenue, USD Million, 2017 - 2028)

  • Stem Cell Therapy

  • Non-Stem Cell Therapy

• Scale Outlook (Revenue, USD Million, 2017 - 2028)

  • Pre-commercial/R&D Scale

  • Commercial Scale

• Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Spain

    • Italy

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE